Vertex Pharmaceuticals Inc
VRTX
Key stats
- Open
- 547.87
- Day high
- 552.27
- Day low
- 542.51
- Previous close
- 547.03
- Volume
- 983.3K
- VWAP
- 544.65
- 52-week high
- 568.67
- 52-week low
- 412.27
- Market cap
- 138.69B
- Shares out
- 253.54M
- Employees
- 6,400
- Listed
- 1991
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
PHARMACEUTICAL PREPARATIONS · BOSTON, MA · vrtx.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 606
- Put open interest
- 595
- Put/call
- 0.98
- At-the-money IV
- 56.0%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 507.50 put | 0.60 | Nov 10, 11:05 AM | 196 | 66 | 125.9% |
| 585 call | 0.62 | Nov 9, 2:24 PM | 83 | 40 | 133.5% |
| 502.50 put | 1.10 | Nov 9, 10:18 AM | 60 | 64 | 151.5% |
| 615 call | 0.60 | Nov 5, 10:13 AM | 59 | 72 | 145.4% |
| 565 call | 0.42 | Nov 12, 3:56 PM | 42 | 11 | 49.1% |
| 520 put | 1.41 | Nov 9, 2:21 PM | 42 | 16 | 93.4% |
Quarterly results
Massive · Nov 3, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $3.44B | $3.33B | $2.99B | $3.19B |
| Gross profit | $2.91B | $2.84B | $2.59B | $2.72B |
| Operating income | $712.90M | $1.25B | $1.14B | $1.21B |
| Net income | $653.60M | $1.10B | $1.03B | $1.19B |
| Diluted EPS | 2.56 | 4.31 | 4.02 | 4.65 |
| Operating cash flow | $643.10M | $1.13B | $1.43B | $498.00M |
| Assets | $32.74B | $27.42B | $26.48B | $25.64B |
| Liabilities | $11.83B | $7.18B | $7.12B | $6.98B |
| Equity | $20.91B | $20.25B | $19.36B | $18.67B |
Technicals
Massive · Nov 12, 2026- 50-day average522.75
- 200-day average483.03
- RSI (14 days)54.9
Short interest
Massive · Oct 30, 2026- Oct 30, 20264.81M shares · 3.4 days to cover
- Oct 15, 20264.26M shares · 3.4 days to cover
- Sep 30, 20264.50M shares · 4.2 days to cover
- Sep 15, 20264.72M shares · 5.0 days to cover
Related companies
MassiveNews coverage
No stories about Vertex Pharmaceuticals Inc right now.